Sentynl Therapeutics’ Nulibry (fosdenopterin) Gains the MHRA’s Approval to Treat Molybdenum Cofactor Deficiency (MoCD) Type A
Shots:
- The MHRA has approved Sentynl’s (wholly-owned by Zydus Lifesciences) Nulibry (fosdenopterin) injection as a treatment of molybdenum cofactor deficiency (MoCD) Type A in Great Britain
- The approval was based on 3 clinical evaluations depicting a 5.5 times decreased death risk and 85.5% survival probability at 3yrs. in Nulibry-treated vs untreated MoCD Type A patients
- Acquired from BridgeBio in Mar 2022, Nulibry is a FIC synthetic cPMP substrate replacement therapy that received the US FDA’s approval in 2021 for the same indication
Ref: Sentynl Therapeutics | Image: Sentynl Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
